Fabry disease in Argentina: an evaluation of patients enrolled in the Fabry Registry

被引:2
|
作者
Politei, J. M. [1 ]
Cabrera, G. [2 ]
Amartino, H. [3 ]
Valdez, R. [4 ]
Masllorens, F. [5 ]
Ripeau, D. [6 ]
Antongiovanni, N. [7 ]
Soliani, A. [8 ]
Luna, P. [9 ]
Cedrolla, M. [10 ]
Fernandez, S. [11 ]
Fainboim, A. [12 ]
机构
[1] Juan Fernandez Hosp, Neurol Serv, RA-1878 Buenos Aires, DF, Argentina
[2] Del Viso Med Ctr, Serv Cardiol, Buenos Aires, DF, Argentina
[3] Austral Hosp, Neuropediatr Serv, Buenos Aires, DF, Argentina
[4] Cent Mil Hosp, Genet Serv, Buenos Aires, DF, Argentina
[5] Posadas Hosp, Genet Serv, Buenos Aires, DF, Argentina
[6] Posadas Hosp, Serv Nephrol, Buenos Aires, DF, Argentina
[7] Pergamino Clin, Serv Nephrol, Buenos Aires, DF, Argentina
[8] Cosme Argerich Hosp, Dermatol Serv, Buenos Aires, DF, Argentina
[9] German Hosp, Dermatol Serv, Buenos Aires, DF, Argentina
[10] High Complex Hosp, Neurol Serv, Formosa, Argentina
[11] Ciperca Srl, Serv Nephrol, Catamarca, Argentina
[12] Ricardo Gutierrez Hosp, Serv Pediat, Buenos Aires, DF, Argentina
关键词
NATURAL-HISTORY DATA; AGALSIDASE BETA TREATMENT; ALPHA-GALACTOSIDASE; RENAL-DISEASE; REPLACEMENT THERAPY; DIALYSIS; FEMALES; LIFE;
D O I
10.1111/ijcp.12081
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims: Fabry disease (FD) is an X-linked inborn error of metabolism caused by alpha-galactosidase A deficiency. The Fabry Registry is an ongoing, global observational database that compiles clinical data from patients with FD. Methods: Demographic and baseline clinical characteristics of Fabry Registry patients enrolled in Argentina were analysed and compared with patients enrolled in the rest of the world (ROW). Baseline clinical parameters included chronic kidney disease (CKD) stage, urine protein-to-creatinine ratio and left ventricular posterior wall thickness. Only data from untreated patients were included. Results: As of 1 October 2010, 3752 patients were enrolled in the Registry, 70 patients from Argentina and 3682 from the ROW. Argentinean male subjects were younger than Fabry Registry male subjects enrolled in ROW: mean current age 32.5 years vs. 39.0 years for men (p = 0.0257 by t-test). The current age (mean +/- standard deviation) of female subjects enrolled in Argentina was not significantly different from that of female subjects enrolled in the ROW: 40.1 +/- 17.28 vs. 43.2 +/- 17.95 years respectively (p = 0.2967). Overall, a smaller percentage of patients from Argentina received ERT compared with patients in the ROW (54% vs. 58% respectively). When evaluated by gender, more men and fewer women in Argentina received ERT compared with ROW (85% vs. 79% for men and 27% vs. 38% for women). A larger proportion of patients in ROW had severe CKD (stage 4 or 5) compared with Argentina (9.8% vs. 0%), most likely because of the older age of the ROW population. Conclusions: The enrolment of Argentinean patients into the Fabry Registry has steadily increased, as has the inclusion of female and paediatric patients with FD. The medical community in Argentina should be aware of FD in these populations, as awareness will facilitate prompt diagnosis and initiation of treatment, thus leading to improved outcomes.
引用
收藏
页码:66 / 72
页数:7
相关论文
共 50 条
  • [2] Demographic characterization of Brazilian patients enrolled in the Fabry Registry
    Martins, A. M.
    Kyosen, S. O.
    Garrote, J.
    Marques, F. M. V.
    Guilhem, J. G.
    Macedo, E.
    Sobral Neto, J.
    Ura, S.
    GENETICS AND MOLECULAR RESEARCH, 2013, 12 (01) : 136 - 142
  • [3] Baseline characteristics of patients enrolled in the Canadian Fabry Disease Initiative
    Sirrs, S.
    Clarke, J. T. R.
    Bichet, D. G.
    Casey, R.
    Lemoine, K.
    Flowerdew, G.
    Sinasac, D. S.
    West, M. L.
    MOLECULAR GENETICS AND METABOLISM, 2010, 99 (04) : 367 - 373
  • [4] End-stage renal disease in patients with Fabry disease: natural history data from the Fabry Registry
    Ortiz, Alberto
    Cianciaruso, Bruno
    Cizmarik, Marta
    Germain, Dominique P.
    Mignani, Renzo
    Oliveira, Joao Paulo
    Villalobos, Jacobo
    Vujkovac, Bojan
    Waldek, Stephen
    Wanner, Christoph
    Warnock, David G.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2010, 25 (03) : 769 - 775
  • [5] Time to treatment benefit for adult patients with Fabry disease receiving agalsidase β: data from the Fabry Registry
    Ortiz, Alberto
    Abiose, Ademola
    Bichet, Daniel G.
    Cabrera, Gustavo
    Charrow, Joel
    Germain, Dominique P.
    Hopkin, Robert J.
    Jovanovic, Ana
    Linhart, Ales
    Maruti, Sonia S.
    Mauer, Michael
    Oliveira, Joao P.
    Patel, Manesh R.
    Politei, Juan
    Waldek, Stephen
    Wanner, Christoph
    Yoo, Han-Wook
    Warnock, David G.
    JOURNAL OF MEDICAL GENETICS, 2016, 53 (07) : 495 - 502
  • [6] Fabry disease: experience of screening dialysis patients for Fabry disease
    Kusano, Eiji
    Saito, Osamu
    Akimoto, Tetsu
    Asano, Yasushi
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2014, 18 (02) : 269 - 273
  • [7] Prevalence of Fabry Disease in Young Patients with Stroke in Argentina
    Reisin, Ricardo C.
    Mazziotti, Julieta
    Leon Cejas, Luciana
    Zinnerman, Alberto
    Bonardo, Pablo
    Fernandez Pardal, Manuel
    Martinez, Alejandra
    Riccio, Patricia
    Ameriso, Sebastian
    Bendersky, Eduardo
    Nofal, Pedro
    Cairola, Patricia
    Jure, Lorena
    Sotelo, Andrea
    Rozenfeld, Paula
    Ceci, Romina
    Casas-Parera, Ignacio
    Sanchez-Luceros, Analia
    JOURNAL OF STROKE & CEREBROVASCULAR DISEASES, 2018, 27 (03): : 575 - 582
  • [8] Agalsidase beta treatment is associated with improved quality of life in patients with Fabry disease: Findings from the Fabry Registry
    Watt, Torquil
    Burlina, Alessandro P.
    Cazzorla, Chiara
    Schoenfeld, Dorothee
    Banikazemi, Maryam
    Hopkin, Robert J.
    Martins, Ana Maria
    Sims, Katherine
    Beitner-Johnson, Dana
    O'Brien, Fanny
    Feldt-Rasmussen, Ulla
    GENETICS IN MEDICINE, 2010, 12 (11) : 703 - 712
  • [9] The Ckd. Qld fabRy Epidemiology (aCQuiRE) study protocol: identifying the prevalence of Fabry disease amongst patients with kidney disease in Queensland, Australia
    Mallett, Andrew
    Kearey, Phoebe
    Cameron, Anne
    Healy, Helen
    Denaro, Charles
    Thomas, Mark
    Lee, Vincent W.
    Stark, Samantha
    Fuller, Maria
    Hoy, Wendy E.
    BMC NEPHROLOGY, 2020, 21 (01)
  • [10] Global reach of over 20 years of experience in the patient-centered Fabry Registry: Advancement of Fabry disease expertise and dissemination of real-world evidence to the Fabry community
    Wanner, Christoph
    Ortiz, Alberto
    Wilcox, William R.
    Hopkin, Robert J.
    Johnson, Jack
    Ponce, Elvira
    Ebels, Johan T.
    Batista, Julie L.
    Maski, Manish
    Politei, Juan M.
    Martins, Ana Maria
    Banikazemi, Maryam
    Linhart, Ales
    Mauer, Michael
    Oliveira, Joao P.
    Weidemann, Frank
    Germain, Dominique P.
    MOLECULAR GENETICS AND METABOLISM, 2023, 139 (03)